Ginkgo Bioworks Holdings, Inc. DNA
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Ginkgo Bioworks Holdings, Inc. (DNA) is a healthcare company listed in the US with a market value of about $623M. In the twelve months to September 30, 2026 it had revenue of $131M and net income of -$251M, a net margin of -192.0%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 17% a year, a 5-year average ROIC of -71%.
About Ginkgo Bioworks
Ginkgo Bioworks is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $54M in 2019 to $170M in 2025, growth of about 21.0% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 32% over three years (dilution for shareholders). It spends 143% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $131M | $170M | $227M | $251M | $478M | $314M | $77M | $54M |
| Net income | -$251M | -$313M | -$547M | -$893M | -$2.1B | -$1.8B | -$127M | -$119M |
| Free cash flow | -$174M | -$179M | -$382M | -$336M | -$304M | -$310M | -$194M | -$67M |
| EPS (diluted) | $-4.17 | $-5.64 | $-10.54 | $-18.37 | $-50.20 | $-55.60 | $-4.00 | $-4.00 |
| Net margin | -192.0% | -183.8% | -240.9% | -355.1% | -440.6% | -583.1% | -165.2% | -220.2% |
| ROIC | — | -33.1% | -47.3% | -64.6% | -100.7% | -109.3% | -23.5% | -11.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $8.00, 17% below the current price; targets range from $5.00 to $11.00; the consensus rating is “Underperform”; expected EPS is $-3.20 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Ginkgo Bioworks pay a dividend?
Not currently.
Is Ginkgo Bioworks a good stock to buy?
We do not give buy or sell advice. Ginkgo Bioworks scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.